BR112017011982A2 - roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco. - Google Patents

roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.

Info

Publication number
BR112017011982A2
BR112017011982A2 BR112017011982A BR112017011982A BR112017011982A2 BR 112017011982 A2 BR112017011982 A2 BR 112017011982A2 BR 112017011982 A BR112017011982 A BR 112017011982A BR 112017011982 A BR112017011982 A BR 112017011982A BR 112017011982 A2 BR112017011982 A2 BR 112017011982A2
Authority
BR
Brazil
Prior art keywords
rodent
drug
cell
methods
assess
Prior art date
Application number
BR112017011982A
Other languages
English (en)
Portuguese (pt)
Inventor
J Murphy Andrew
Burova Elena
Venus Lai Ka-Man
Tang Yajun
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of BR112017011982A2 publication Critical patent/BR112017011982A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A61K49/0008—Screening agents using (non-human) animal models or transgenic animal models or chimeric hosts, e.g. Alzheimer disease animal model, transgenic model for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0331—Animal model for proliferative diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112017011982A 2014-12-09 2015-12-09 roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco. BR112017011982A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462089549P 2014-12-09 2014-12-09
US201562106525P 2015-01-22 2015-01-22
PCT/US2015/064626 WO2016094481A1 (en) 2014-12-09 2015-12-09 Non-human animals having a humanized cluster of differentiation 274 gene

Publications (1)

Publication Number Publication Date
BR112017011982A2 true BR112017011982A2 (pt) 2018-01-16

Family

ID=55024286

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011982A BR112017011982A2 (pt) 2014-12-09 2015-12-09 roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.

Country Status (27)

Country Link
US (4) US9913461B2 (enExample)
EP (3) EP4399969A3 (enExample)
JP (3) JP2018500896A (enExample)
KR (2) KR102316842B1 (enExample)
CN (2) CN113412818B (enExample)
AU (3) AU2015360667B2 (enExample)
BR (1) BR112017011982A2 (enExample)
CA (1) CA2968675C (enExample)
CY (1) CY1123723T1 (enExample)
DK (2) DK3230320T3 (enExample)
ES (2) ES2841353T3 (enExample)
FI (1) FI3808775T3 (enExample)
HR (2) HRP20202034T1 (enExample)
HU (2) HUE052606T2 (enExample)
IL (3) IL282649B (enExample)
LT (2) LT3230320T (enExample)
MX (1) MX2017007636A (enExample)
NZ (2) NZ731954A (enExample)
PL (1) PL3808775T3 (enExample)
PT (2) PT3230320T (enExample)
RS (2) RS65664B1 (enExample)
RU (1) RU2711729C2 (enExample)
SG (2) SG11201703931QA (enExample)
SI (2) SI3230320T1 (enExample)
SM (2) SMT202100148T1 (enExample)
WO (1) WO2016094481A1 (enExample)
ZA (1) ZA201703263B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2841353T3 (es) * 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
HUE054612T2 (hu) 2015-11-20 2021-09-28 Regeneron Pharma Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok
US10582702B2 (en) 2016-02-04 2020-03-10 Regeneron Pharmaceuticals, Inc. Non-human animals having an engineered ANGPTL8 gene
SG10202001578RA (en) 2016-02-29 2020-04-29 Regeneron Pharma Rodents having a humanized tmprss gene
DK3476865T5 (da) 2016-06-28 2024-09-09 Biocytogen Pharmaceuticals Beijing Co Ltd Fremgangsmåde til konstruktion af pd-1-gen-modificeret humaniseret dyremodel og anvendelse deraf
WO2018041120A1 (en) 2016-08-31 2018-03-08 Beijing Biocytogen Co., Ltd Genetically modified non-human animal with human or chimeric tigit
CN107815467B (zh) * 2016-08-31 2021-03-16 百奥赛图(北京)医药科技股份有限公司 人源化基因改造动物模型的制备方法及应用
CN107815466B (zh) 2016-08-31 2020-03-13 百奥赛图江苏基因生物技术有限公司 人源化基因改造动物模型的制备方法及应用
DK3507373T5 (da) 2016-08-31 2024-09-02 Biocytogen Pharmaceuticals Beijing Co Ltd Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1
BR112019011186A2 (pt) 2016-12-01 2019-10-08 Regeneron Pharmaceuticals, Inc. conjugado de anticorpo radiomarcado, composto, e, métodos de imageamento e para tratamento de um tumor.
CN109666701B (zh) * 2017-10-13 2021-08-24 百奥赛图(北京)医药科技股份有限公司 一种pd-1基因修饰人源化动物模型的构建方法及其应用
WO2019072241A1 (en) 2017-10-13 2019-04-18 Beijing Biocytogen Co., Ltd NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
US11419318B2 (en) 2017-11-30 2022-08-23 Regeneran Pharmaceuticals, Inc. Genetically modified rat comprising a humanized TRKB locus
CN109913493B (zh) 2017-12-12 2021-03-16 百奥赛图江苏基因生物技术有限公司 人源化cd3基因改造动物模型的制备方法及应用
JP7328243B2 (ja) 2018-03-26 2023-08-16 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療薬を試験するためのヒト化げっ歯類
SG11202011284RA (en) 2018-07-16 2020-12-30 Regeneron Pharma Non-human animal models of ditra disease and uses thereof
CN110846321B (zh) * 2018-08-21 2021-11-19 中国科学院动物研究所 一种突变基因及其用于构建斑色鱼鳞癣小型猪模型的用途
WO2020081585A1 (en) * 2018-10-15 2020-04-23 The Brigham And Women's Hospital, Inc. The long non-coding rna inca1 and homo sapiens heterogeneous nuclear ribonucleoprotein h1 (hnrnph1) as therapeutic targets for immunotherapy
CN109452229B (zh) * 2018-11-19 2021-10-22 百奥赛图(北京)医药科技股份有限公司 狗源化pd-1基因改造动物模型的制备方法及应用
CN109979539B (zh) * 2019-04-10 2020-10-02 电子科技大学 基因序列优化方法、装置及数据处理终端
CN114621971A (zh) * 2021-02-19 2022-06-14 百奥赛图(北京)医药科技股份有限公司 经遗传修饰的非人动物及其构建方法和应用
CN112999368A (zh) * 2021-04-09 2021-06-22 广东药康生物科技有限公司 人源化模型进行药效评价方法的建立

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5670356A (en) 1994-12-12 1997-09-23 Promega Corporation Modified luciferase
US6485964B1 (en) * 1995-03-20 2002-11-26 Arris Pharmaceutical Corporation Transgenic mammals lacking expression of erythropoietin or of erythropoietin receptor, transgenic mammals expressing chimeric erythropoietin receptors, constructs for producing the transgenic mammals and uses therefor
GB9517780D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
GB9517779D0 (en) 1995-08-31 1995-11-01 Roslin Inst Edinburgh Biological manipulation
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
CA2414331C (en) 2000-06-28 2011-11-29 Genetics Institute, Llc. Pd-l2 molecules: novel pd-1 ligands and uses therefor
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002086083A2 (en) 2001-04-20 2002-10-31 Mayo Foundation For Medical Education And Research Methods of enhancing cell responsiveness
DE10211088A1 (de) * 2002-03-13 2003-09-25 Ugur Sahin Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
ES2350687T3 (es) 2002-07-03 2011-01-26 Ono Pharmaceutical Co., Ltd. Composiciones de inmunopotenciación.
JP2006517096A (ja) * 2002-12-16 2006-07-20 ジェネンテック・インコーポレーテッド ヒトｃｄ２０を発現するトランスジェニックマウス
CA2508660C (en) 2002-12-23 2013-08-20 Wyeth Antibodies against pd-1 and uses therefor
ES2364335T3 (es) * 2003-12-24 2011-08-31 G2 Inflammation Pty Ltd Mamífero no humano transgénico que comprende un polinucleótido que codifica el c5ar humano o humanizado.
WO2005060739A1 (en) 2003-12-24 2005-07-07 G2 Inflammation Pty Ltd Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar
HUE070155T2 (hu) 2004-10-06 2025-05-28 Mayo Found Medical Education & Res B7-H10 és PD-1 vesesejtes karcinóma kezelésében
ES2667169T3 (es) 2004-10-19 2018-05-09 Regeneron Pharmaceuticals, Inc. Método para generar un animal no humano homocigótico para una modificación genética
PL1907424T3 (pl) 2005-07-01 2015-12-31 Squibb & Sons Llc Ludzkie monoklonalne przeciwciała wobec liganda zaprogramowanej śmierci 1 (PD-L1)
US8216996B2 (en) 2006-03-03 2012-07-10 Ono Pharmaceutical Co., Ltd. Multimer of extracellular domain of cell surface functional molecule
JP6087503B2 (ja) 2008-09-26 2017-03-08 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド ヒト抗ｐｄ−１、ｐｄ−ｌ１、及びｐｄ−ｌ２抗体とその用途
CN102575227A (zh) 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 表达多种免疫调节剂的工程改造细胞及其应用
CN112690250B (zh) * 2008-12-18 2024-03-08 伊拉兹马斯大学鹿特丹医学中心 表达人源化抗体的非人转基因动物及其用途
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
RU2425880C2 (ru) * 2009-07-30 2011-08-10 Учреждение Российской академии наук Институт общей генетики им. Н.И. Вавилова РАН Способ получения трансгенных мышей
US8518392B2 (en) 2009-08-14 2013-08-27 Regeneron Pharmaceuticals, Inc. Promoter-regulated differentiation-dependent self-deleting cassette
AU2010286516B2 (en) * 2009-08-28 2016-10-06 Regeneron Pharmaceuticals, Inc. Antikine antibodies that bind to multiple CC chemokines
ES2700852T3 (es) 2009-10-06 2019-02-19 Regeneron Pharma Ratones modificados genéticamente e injerto
US20120263692A1 (en) 2009-11-16 2012-10-18 Bertone Alicia L Engineered Xenogeneic Cells for Repair of Biological Tissue
RU2706200C2 (ru) * 2009-11-24 2019-11-14 Медиммьюн Лимитед Специфические связывающие агенты против в7-н1
NO2516457T3 (enExample) * 2009-12-21 2018-08-11
US8507663B2 (en) * 2010-04-06 2013-08-13 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of CD274/PD-L1 gene
CN105861553B (zh) 2011-02-15 2020-08-14 再生元制药公司 人源化m-csf小鼠
HUE035652T2 (en) * 2011-10-28 2018-05-28 Regeneron Pharma Genetically modified major histocompatibility complex mice
KR102113108B1 (ko) 2011-10-28 2020-05-20 리제너론 파아마슈티컬스, 인크. 키메라 주요 조직적합성 복합체 （ｍｈｃ） 제ｉｉ부류 분자들을 발현하는 유전자전이 마우스
DK2663575T3 (en) 2011-10-28 2014-12-15 Regeneron Pharma HUMANIZED IL-6 and IL-6 receptor
WO2013078230A1 (en) 2011-11-23 2013-05-30 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
CN103987405B (zh) 2011-11-28 2017-03-29 默克专利股份公司 抗pd‑l1抗体及其用途
CN111499755A (zh) 2012-08-03 2020-08-07 丹娜法伯癌症研究院 抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
US20140047572A1 (en) * 2012-08-13 2014-02-13 University Of Rochester Thrombopoietin mimetics for the treatment of radiation or chemical induced bone marrow injury
ES2701093T3 (es) 2012-08-21 2019-02-20 Sanofi Biotechnology Métodos para tratar o prevenir el asma administrando un antagonista de IL-4R
IL307969B1 (en) 2012-09-07 2025-10-01 Regeneron Pharma Genetically modified non-human animals and methods of using them
CA2887706C (en) 2012-11-05 2022-08-02 Regeneron Pharmaceuticals Genetically modified non-human animals and methods of use thereof
EP2948475A2 (en) 2013-01-23 2015-12-02 AbbVie Inc. Methods and compositions for modulating an immune response
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
WO2014130671A1 (en) * 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Mice expressing humanized t-cell co-receptors
US20150342163A1 (en) 2013-02-22 2015-12-03 Regeneron Pharmaceuticals, Inc. Genetically modified major histocompatibility complex mice
KR102211267B1 (ko) 2013-02-22 2021-02-04 리제너론 파아마슈티컬스, 인크. 사람화된 주요 조직적합성 복합체를 발현하는 마우스
SI2986729T1 (sl) * 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
CN103242448B (zh) * 2013-05-27 2015-01-14 郑州大学 一种全人源化抗pd-1单克隆抗体及其制备方法和应用
WO2014197369A1 (en) 2013-06-06 2014-12-11 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
RU2018136614A (ru) 2013-09-23 2018-11-27 Регенерон Фармасьютикалс, Инк. Отличные от человека животные с гуманизированным геном сигнального регуляторного белка
EP3071024B1 (en) 2013-11-19 2018-09-05 Regeneron Pharmaceuticals, Inc. Non-human animals having a humanized b-cell activating factor gene
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
ES2794942T3 (es) 2014-04-08 2020-11-19 Regeneron Pharma Animales no humanos que tienen receptores Fc-gamma humanizados
NO2785538T3 (enExample) 2014-05-07 2018-08-04
DK3145307T3 (en) 2014-05-19 2019-04-15 Regeneron Pharma RE-MODIFIED NON-HUMAN ANIMALS EXPRESSING HUMAN EPO
SG11201609638RA (en) 2014-06-19 2016-12-29 Regeneron Pharma Non-human animals having a humanized programmed cell death 1 gene
PL3223605T3 (pl) 2014-11-24 2021-04-19 Regeneron Pharmaceuticals, Inc. Zwierzęta inne niż ludzie eksprymujące humanizowany kompleks CD3
DK3466255T3 (da) 2014-12-05 2021-05-03 Regeneron Pharma Ikke-humane dyr med en humaniseret klynge af differentiering af 47-gen
ES2841353T3 (es) 2014-12-09 2021-07-08 Regeneron Pharma Animales no humanos que tienen un gen del grupo de diferenciación 274 humanizado
HUE054612T2 (hu) 2015-11-20 2021-09-28 Regeneron Pharma Humanizált limfocitaaktiváló gén 3-t tartalmazó nem-humán állatok
DK3507373T5 (da) 2016-08-31 2024-09-02 Biocytogen Pharmaceuticals Beijing Co Ltd Genetisk modificeret ikke-menneskeligt dyr med human eller kimær pd-l1

Also Published As

Publication number Publication date
CA2968675C (en) 2023-10-17
RS61218B1 (sr) 2021-01-29
NZ770783A (en) 2024-11-29
HRP20240855T1 (hr) 2024-10-11
DK3808775T3 (da) 2024-07-01
HRP20202034T1 (hr) 2021-02-19
NZ731954A (en) 2024-11-29
EP4399969A2 (en) 2024-07-17
JP2021003130A (ja) 2021-01-14
US20240389563A1 (en) 2024-11-28
AU2021286369B2 (en) 2025-03-27
JP7145920B2 (ja) 2022-10-03
ES2982515T3 (es) 2024-10-16
ES2841353T3 (es) 2021-07-08
PL3808775T3 (pl) 2024-08-19
HUE052606T2 (hu) 2021-05-28
RU2017123754A (ru) 2019-01-10
AU2021286369A1 (en) 2022-01-20
CY1123723T1 (el) 2022-03-24
AU2015360667A1 (en) 2017-06-08
SI3808775T1 (sl) 2024-08-30
US9913461B2 (en) 2018-03-13
IL275864A (en) 2020-08-31
EP3230320B1 (en) 2020-10-07
JP2018500896A (ja) 2018-01-18
SI3230320T1 (sl) 2021-02-26
AU2015360667B2 (en) 2021-09-23
JP7488861B2 (ja) 2024-05-22
SG10202100792XA (en) 2021-03-30
RU2711729C2 (ru) 2020-01-21
EP3808775A1 (en) 2021-04-21
CN107257624A (zh) 2017-10-17
ZA201703263B (en) 2023-02-22
EP3230320A1 (en) 2017-10-18
RU2017123754A3 (enExample) 2019-06-24
US12089575B2 (en) 2024-09-17
CA2968675A1 (en) 2016-06-16
CN107257624B (zh) 2021-07-13
FI3808775T3 (fi) 2024-07-02
CN113412818A (zh) 2021-09-21
US10881086B2 (en) 2021-01-05
EP4399969A3 (en) 2024-10-30
WO2016094481A1 (en) 2016-06-16
IL252695A0 (en) 2017-08-31
JP2022184973A (ja) 2022-12-13
US20210105983A1 (en) 2021-04-15
EP3808775B1 (en) 2024-04-17
SMT202400313T1 (it) 2024-09-16
SMT202100148T1 (it) 2021-05-07
MX2017007636A (es) 2018-03-28
SG11201703931QA (en) 2017-06-29
PT3230320T (pt) 2021-01-08
HUE067123T2 (hu) 2024-10-28
LT3808775T (lt) 2024-07-10
IL282649A (en) 2021-06-30
RS65664B1 (sr) 2024-07-31
IL282649B (en) 2022-07-01
CN113412818B (zh) 2022-11-04
KR102457921B1 (ko) 2022-10-25
DK3230320T3 (da) 2021-01-11
US20160157469A1 (en) 2016-06-09
LT3230320T (lt) 2021-01-11
PT3808775T (pt) 2024-07-09
IL275864B (en) 2021-05-31
KR20210130251A (ko) 2021-10-29
KR20170101910A (ko) 2017-09-06
US20180160663A1 (en) 2018-06-14
AU2025204751A1 (en) 2025-07-17
KR102316842B1 (ko) 2021-10-25
IL252695B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
BR112017011982A2 (pt) roedor, polipeptídeo pd-l1, célula ou tecido isolado de roedor, célula-tronco embrionária de roedor, embrião de roedor, e, métodos para produção de um roedor, para reduzir o crescimento do tumor em um roedor, para matar células tumorais em um roedor, para avaliar as propriedades farmacocinéticas de um fármaco e para avaliar a eficácia de um fármaco.
BR112016029650A2 (pt) roedor, polipeptídeo pd-1, célula isolada ou tecido de roedor, célula-tronco embrionária de roedor, métodos de produzir um roedor, de reduzir o crescimento de tumor em um roedor, de matar células tumorais em um roedor e de avaliar as propriedades farmacocinéticas de uma droga que direciona pd-1 humano, e, modelo de tumor de roedor?
BR112018010158A2 (pt) roedor, polipeptídeo lag-3 humanizado, célula ou tecido, célula-tronco embrionária e embrião de roedor, métodos para produzir um roedor, para avaliar a eficácia antitumoral e as propriedades farmacocinéticas de uma droga
BR112017010490A2 (pt) roedor, polipeptídeo cd47, célula ou tecido de roedor isolado, célula-tronco emprionária de roedor, embrião de roedor, e, métodos de produzir um roedor, de fornecimento de um roedor, de enxerto de células humanas em um roedor, de avaliação de eficácia terapêutica de uma droga direcionada a células humanas e de avaliar as propriedades farmacocinéticas, de avaliar a toxicidade específica e inespecífica de uma droga direcionada ao cd47 humano.
CL2020000345A1 (es) Mezclas agrícolas.
EP4317445A3 (en) Humanized c5 and c3 animals
BR112016011003A2 (pt) animal roedor geneticamente modificado, célula tronco embrionária de camundongo, embrião de camundongo, e, métodos para fabricar um animal roedor e para enxertar células humanas em um camundongo
BR112016025745A2 (pt) roedor, camundongo, métodos para produção de um roedor e de um camundongo e para triagem de antagonista
BR112015029904A2 (pt) animais geneticamente estéreis
HRP20251062T1 (hr) Neljudske životinje koje imaju gen humaniziranog proteina za reguliranje signala
EA202090931A2 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
Scerbo et al. Ventx factors function as Nanog-like guardians of developmental potential in Xenopus
MX2019012311A (es) Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso.
EP3468356A4 (en) GENETICALLY MODIFIED CELLS, TISSUES AND ORGANS FOR THE TREATMENT OF A DISEASE
MX380555B (es) Combinación de anticuerpos anti-gen 3 de la activación de linfocito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para usarse en el tratamiento de tumores.
BR112016006261A2 (pt) camundongo, célula ou tecido de camundongo isolado, e, métodos para produzir um camundongo, para enxertar células humanas em um camundongo e para avaliar a eficácia terapêutica de uma droga que alveja células humanas
AR100216A1 (es) Edición de genes multiplexados
BR112016002385A2 (pt) animal não humano, célula, tecido ou embrião, vetor de alvejamento, constructo de vetor de alvejamento, e, métodos para produzir um animal não humano e para modificar um lócus de incrna em uma célula pluripotente
BR112016026245A2 (pt) ?roedor, e, métodos para fazer um roedor humanizado, para fazer um camundongo com dpp4 humanizado, para fazer um roedor transgênico humanizado e para determinar a eficácia terapêutica in vivo de um antagonista da dpp4 específica para humanos no roedor?
EP4069821A4 (en) SYSTEM FOR PRODUCING CULTURED MEAT, TISSUES AND RELATED PRODUCTS FROM CELLS
BR112018001232A2 (pt) pd-l1 que expressa células-tronco hematopoéticas e usos
O’Rourke et al. Biology and diseases of amphibians
MX2018009513A (es) Animales no humanos que tienen un gen angptl8 modificado genéticamente.
PH12019502663A1 (en) Methods for gender determination of avian embryos in unhatched eggs and means thereof
MX2020003123A (es) Aves con genoma editado.

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]